The FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

Traditional approval was supported by BREAKWATER arm B showing PFS 12.8 vs 7.1 months (HR, 0.53) and OS 30.3 vs 15.1 months (HR, 0.49) versus control. Objective response improved with the ...

Gorlin-Goltz syndrome (nevoid basal cell carcinoma syndrome) is a rare autosomal dominant tumor-predisposition disorder characterized by multiple basal cell carcinomas (BCCs), odontogenic keratocysts ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...

The father of two said he has already undergone surgery to have the cancer removed, but will continue to monitor his diagnosis BRANDON FRANKEL/Instagram Gabourey Sidibe’s husband, Brandon Frankel, ...

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...

Mayo Clinic testing Israeli magnetic-heating technology as cancer treatment The Rochester-based health system is the first in the U.S. to install the induction system that targets and kills cancer ...

NEW YORK – Pfizer is hoping to seek US regulatory approval for the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) plus chemotherapy as a first-line treatment for BRAF ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...